GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (BUE:GSK) » Definitions » Cyclically Adjusted PS Ratio

GSK (BUE:GSK) Cyclically Adjusted PS Ratio : 2.15 (As of May. 17, 2024)


View and export this data going back to . Start your Free Trial

What is GSK Cyclically Adjusted PS Ratio?

As of today (2024-05-17), GSK's current share price is ARS12351.50. GSK's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ARS5,747.21. GSK's Cyclically Adjusted PS Ratio for today is 2.15.

The historical rank and industry rank for GSK's Cyclically Adjusted PS Ratio or its related term are showing as below:

BUE:GSK' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.57   Med: 2.1   Max: 2.72
Current: 2.12

During the past years, GSK's highest Cyclically Adjusted PS Ratio was 2.72. The lowest was 1.57. And the median was 2.10.

BUE:GSK's Cyclically Adjusted PS Ratio is ranked better than
50.87% of 747 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs BUE:GSK: 2.12

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

GSK's adjusted revenue per share data for the three months ended in Mar. 2024 was ARS958.211. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ARS5,747.21 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


GSK Cyclically Adjusted PS Ratio Historical Data

The historical data trend for GSK's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Cyclically Adjusted PS Ratio Chart

GSK Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.35 1.82 2.11 1.75 1.73

GSK Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.73 1.66 1.78 1.73 2.03

Competitive Comparison of GSK's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted PS Ratio falls into.



GSK Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

GSK's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=12351.50/5747.21
=2.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, GSK's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=958.211/131.6000*131.6000
=958.211

Current CPI (Mar. 2024) = 131.6000.

GSK Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 9.804 99.800 12.928
201409 9.946 100.000 13.089
201412 10.754 99.900 14.166
201503 9.530 99.600 12.592
201506 10.686 100.100 14.049
201509 11.323 100.200 14.871
201512 15.431 100.400 20.226
201603 16.562 100.400 21.709
201606 16.684 101.000 21.739
201609 18.849 101.500 24.439
201612 18.930 102.200 24.376
201703 17.861 102.700 22.887
201706 19.764 103.500 25.130
201709 23.208 104.300 29.283
201712 24.584 105.000 30.812
201803 25.687 105.100 32.164
201806 30.543 105.900 37.955
201809 48.930 106.600 60.405
201812 49.040 107.100 60.258
201903 49.538 107.000 60.927
201906 55.375 107.900 67.538
201909 81.085 108.400 98.439
201912 86.093 108.500 104.422
202003 87.111 108.600 105.560
202006 81.281 108.800 98.314
202009 103.106 109.200 124.256
202012 -13.624 109.400 -16.389
202103 114.997 109.700 137.954
202106 96.043 111.400 113.458
202109 109.780 112.400 128.532
202112 117.000 114.700 134.239
202203 125.078 116.500 141.290
202206 101.064 120.500 110.374
202209 150.683 122.300 162.141
202212 184.131 125.300 193.389
202303 203.974 126.800 211.695
202306 212.573 129.400 216.187
202309 429.051 130.100 433.998
202312 446.536 130.500 450.300
202403 958.211 131.600 958.211

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GSK  (BUE:GSK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


GSK Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of GSK's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK (BUE:GSK) Business Description

Industry
Address
980 Great West Road, Brentford, Middlesex, GBR, TW8 9GS
In the pharmaceutical industry, GSK ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

GSK (BUE:GSK) Headlines

From GuruFocus

Ridgewood Investments LLC Buys 3, Sells 2 in 4th Quarter

By GuruFocus Research GuruFocus Editor 01-20-2023

GSK: Undervalued at Peak Pessimism

By Nathan Aisenstadt 11-19-2023

Signature Wealth Management Group Buys 3, Sells 2 in 4th Quarter

By GuruFocus Research GuruFocus Editor 01-10-2023

GSK Enters Agreement to Acquire Aiolos Bio

By Business Wire 01-09-2024